FDC Limited approves results for quarter ended Sep 30, 2026 and share buyback proposal
FDC · Pharmaceuticals & Biotechnology
What the filing says
- Unaudited standalone and consolidated results for quarter and half year ended September 30, 2026 approved on October 27, 2026
- Board approved buyback of up to 24,00,000 equity shares at ₹500 per share, aggregate amount not exceeding ₹120 crore
- Record Date for buyback fixed as Friday, November 13, 2026; buyback to be made through the Tender Offer route
Why it's rated major development: the year-on-year change is 73% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. Tuesday, October 27, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other dividend / buyback / bonus filings this fortnight
- Kaveri Seed Company Limited announces Q2 2026 results, interim dividend, and new CFO
- Kaveri Seed Company Limited announces Q2 results, interim dividend, and CFO appointment
- Vedanta Limited reports record Q2 and H1 FY27 results; Q2 PAT up 151% YoY
- Manba Finance Q2 FY27 PAT ₹1,373.41 lakh vs ₹1,139.81 lakh; second interim dividend declared
- DCM Shriram Ltd reports Sept 2026 quarter results and declares ₹4.00 interim dividend
- DCM Shriram Ltd announces Q2 FY 2026-27 results, interim dividend, and JV update
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.